FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 38 filers reported holding FUSION PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,058,553 | -44.3% | 1,560,982 | 0.0% | 1.62% | -32.6% |
| Q2 2023 | $7,289,786 | +23.9% | 1,560,982 | 0.0% | 2.40% | -0.8% |
| Q1 2023 | $5,884,902 | +19.7% | 1,560,982 | -0.0% | 2.42% | +13.3% |
| Q4 2022 | $4,917,100 | +4.6% | 1,560,984 | 0.0% | 2.14% | +24.5% |
| Q3 2022 | $4,699,000 | +20.9% | 1,560,984 | +0.0% | 1.72% | -12.3% |
| Q2 2022 | $3,887,000 | -68.7% | 1,560,982 | -2.3% | 1.96% | -66.7% |
| Q1 2022 | $12,419,000 | +90.8% | 1,598,377 | 0.0% | 5.88% | +115.9% |
| Q4 2021 | $6,509,000 | -48.6% | 1,598,377 | -0.0% | 2.72% | -39.2% |
| Q3 2021 | $12,659,000 | +0.4% | 1,598,379 | +0.0% | 4.47% | -10.0% |
| Q2 2021 | $12,613,000 | -26.4% | 1,598,377 | -0.0% | 4.97% | -9.6% |
| Q1 2021 | $17,135,000 | -8.8% | 1,598,379 | 0.0% | 5.50% | -11.2% |
| Q4 2020 | $18,781,000 | – | 1,598,379 | – | 6.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,670,516 | $9,543,342 | 3.52% |
| ADAMS STREET PARTNERS LLC | 2,947,809 | $7,664,303 | 2.68% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,560,982 | $4,058,553 | 1.62% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,354,258 | $3,521,071 | 0.64% |
| Avidity Partners Management LP | 5,781,850 | $15,032,810 | 0.60% |
| Eagle Health Investments LP | 579,769 | $1,507,399 | 0.33% |
| Perceptive Advisors | 2,751,395 | $7,153,627 | 0.24% |
| Ghost Tree Capital, LLC | 243,287 | $632,546 | 0.21% |
| Sio Capital Management, LLC | 246,036 | $639,694 | 0.20% |
| Artal Group S.A. | 1,725,000 | $4,485 | 0.19% |